De novo cryptogenic hepatitis after sustained eradication of hepatitis C following liver transplantation
| Autor: | Daniel F. Schafer, Joyce Rogge, Lynne Weaver, Sandeep Mukherjee |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
medicine.medical_specialty Cirrhosis medicine.medical_treatment Alpha interferon Liver transplantation Gastroenterology Liver disease chemistry.chemical_compound Postoperative Complications Liver Function Tests Recurrence Internal medicine Humans Medicine Hepatitis Chronic Retrospective Studies Transplantation medicine.diagnostic_test business.industry Ribavirin virus diseases Hepatitis C Middle Aged medicine.disease digestive system diseases Liver Transplantation chemistry Female Surgery business Liver function tests |
| Zdroj: | Transplantation Proceedings. 36:1494-1497 |
| ISSN: | 0041-1345 |
| DOI: | 10.1016/j.transproceed.2004.05.058 |
| Popis: | Patients with recurrent hepatitis C (HCV) after liver transplantation (OLT) are often treated with interferon and ribavirin in an attempt to eradicate HCV and prevent cirrhosis. We report four patients who developed de novo cryptogenic hepatitis following sustained eradication of recurrent HCV, which led to decompensated liver disease in two patients, both of whom required listing for retransplantation. Between September 2000 and October 2001, 38 consecutive patients with recurrent HCV were treated with interferon alpha 2b and ribavirin, of whom eight patients (21%) developed a sustained response to HCV eradication. Four of these patients developed cryptogenic hepatitis, which led to decompensated cirrhosis in two patients. Both patients were listed for retransplantation but died on the waiting list. No etiology for liver disease was identified despite extensive investigations in all four patients including postmortem analysis in the two patients. We hypothesize that these individuals developed an aberrant immune response leading to allograft injury whose severity may be determined by underlying haplotype, degree of immunosuppression, presence/absence of HCV, and duration of treatment. We have not found any similar reports in the literature but anticipate more cases to be reported given the universal use of antiviral therapy for recurrent HCV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect